Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

March 19, 2021 by Alan Khadavi

Xolair for Idiopathic Anaphylaxis

Xolair for idiopathic anaphylaxis was recently studied in a randomized double-blind, placebo-controlled study. We have discussed idiopathic anaphylaxis in the past in a blog post.

It is a diagnosis of exclusion, so there is no inciting agent. Epinephrine followed by systemic steroids are the mainstays of therapy for acute events. There is no prophylactic therapy that reliably prevents anaphylaxis.

Anaphylaxis is a systemic reaction associated with the release of mediators from mast cells and basophils. Signs and symptoms are flushing, hives, congestion, eye irritation, bronchospasm, swelling of the tongue, throat, palms and soles, GI cramping, light headedness and loss of conciousness.

Common causes are allergic reactions to foods, drugs or stinging insects. A factor is identified in up to 50% of the patients with recurrent episodes. Idiopathic anaphylaxis is categorized as frequent (2 episodes in past 2 months or greater than 6 episodes in past year) or infrequent (less than 6 episodes a year).

Management consists of epinephrine, airway protection and support of circulation.

Xolair (omalizumab) is approved for the treatment of moderate to severe asthma and chronic urticaria. (More recently nasal polyps). Xolair targets IgE and several reports showed it worked for idiopathic anaphylaxis, systemic mastocytosis or mast cell activation syndrome.

A recent study completed 16 patients in a trial of Xolair for idiopathic anaphylaxis. No statistically significant difference was demonstrated between the placebo and treated groups. There was a trend for efficacy in the treatment group, but it wasn’t significant.

The key messages from this study are:

  • Xolair for idiopathic anaphylaxis cannot be expected to prevent subsequent episodes of anaphylaxis, and if it administered, careful monitoring is required to evaluate success.
  • Because idiopathic anaphylaxis can decrease in severity and frequency, with time, any intervention must be evaluated on a case by case basis for efficacy.

Although there are several case reports in the literature that relate efficacy of Xolair for idiopathic anaphylaxis, these studies only enrolled 1 case.

Idiopathic Anaphylaxis-Workup and Treatment

 

Filed Under: Anaphylaxis, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page